• US: +1-408-610-2300
  • Toll Free: +1-866-831-4085
  • Login / Register
  • Home
  • » Biotechnology
  • » In Situ Hybridization (ISH) Market Size, 2024 | Global Industry Report
In Situ Hybridization (ISH) Market Size, 2024 | Global Industry Report

In Situ Hybridization Market Size Analysis, Segmentation, Industry Outlook and Forecasts, 2018 - 2024

Report ID: MN17617969  |  Published: March 2018  |  No of Pages: 242
Format: Electronic (PDF)  |  Industry: Biotechnology  |  Publisher: WINTERGREEN

The Global In Situ Hybridization Market is subject to witness a substantial growth due to the rising demand for molecular diagnostic tools and increasing adoption of ISH technology. Growing prevalence of chronic diseases along with rising demand for rapid diagnostic techniques are anticipated to foster market growth over the forecast period. Globally, the market is predicted to grow at CAGR of 7.8% in the forecast period, providing numerous opportunities for market players to invest for research and development in the In Situ hybridization market.

The conventional methodologies such as clinical trials were influenced by factors such as the growing competition, rising prices of medicines and strict governmental laws to limit adverse effects on the environment. With advent of the In Situ hybridization, such factors are significantly diminished due numerous advantages provided with the use of the In Situ hybridization. Benefits associated with adoption of In Situ hybridization are superior performance, successful trials, reliability and short timeframes for execution of clinical trial, and cost-effectiveness.

Rising prevalence of cancer-related diseases is expected to boost market demand for In Situ hybridization over the upcoming years. In addition, increasing adoption of DNA probe-based diagnostics for identification of diseases that are caused by pathogen or bacteria is estimated to drive market growth. Rise in the number of incidence related to genetic disorders, solid tumors, leukemia, autism, and other syndromes are predicted to stimulate market demand for In Situ hybridization over the forecast period.

The market is broadly categorized into major four segments based on the product type such as instruments, kits & probes, software and services. The instruments is considered as one of the fastest growing segment in the In Situ hybridization market with substantial revenue generation in the last few years. Growing popularity of the instruments segment among healthcare professionals is attributed to the rise in the demand from diagnostic and research laboratories. The kits & probes segment has also witnessed substantial growth owing to the growing incidence of target disorders such as cancer.

The market is divided by region as North America, Europe, Asia-Pacific, Latin America and Africa. North America has shown major growth in recent years owing to the rise in the implementation of latest technologies in pharmaceuticals & medicine sector, higher penetration rates, increase in the demand for disposable devices from healthcare professionals, and existence of well-established infrastructure.

Asia-Pacific region is predicted to hold major market share in the In Situ hybridization market with massive growth in forecast period. Countries such as India, China and Singapore are leading the Asia-Pacific market with increasing healthcare expenditure, growing prevalence of cancer related diseases, presence of high-unmet patient needs, and significant investment by leading industry players considering potential growth opportunities in the region.

The key players in the In Situ hybridization market are Thermo Fisher Scientific Co., Leica BiosystemsNussloch GmbH, BIOVIEW, Inc., Agilent Technologies, Inc., Merck KGaA, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., NeoGenomics Laboratories, Inc., Advanced Cell Diagnostics, Inc., and Oxford Gene Technology Co.

Market Segment:

Market Leaders
• Leica Biosystems Nussloch GmbH
• Thermo Fisher Scientific
• F. Hoffmann-La Roche AG
• Abbott Laboratories
• Agilent Technologies
• PerkinElmer
• Qiagen / Exiqon A/S
• Merck KGaA
• BioGenex Laboratories
• BioTechne / Advanced Cell Diagnostics (ACD)

Key Topics
• In Situ Hybridization
• Molecular Diagnostics
• Cervical Cancer Stain
• Fish Steps Reduction
• Fluorescence In Situ Hybridization (FISH)
• In Situ Hybridization (ISH)
• FISH Probe Kit
• Cancer
• Chromosonal Abnormalities
• Infectious Diseases
• Inflammatory Diseases
• Fluorescence In Situ Hybridization (FISH)
• Chromogenic In Situ Hybridization (CISH)
• Human Genetic Tests
• Microbial Tests
• In Vitro Diagnostics
• System for the Analysis of Solid Tumors
• Hybridization Technique
• Detection of Long Non-
• Coding DNA
• Coding RNA

What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service
  • 100% Secure Payments
  • Our Promise
  • 100% Service Assurance
  • Market Monitoring
  • Service Flexibility
  • 24X5 Care available